Skip to content
Home
Company
About Us
Leadership
Management
Board of Directors
Scientific
Advisory Board
Science
Overview
ALX148
Publications
Pipeline
Pipeline
Clinical Trials
Expanded
Access Policy
Careers
Current Jobs
How to Apply
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact
Antibodies to SIRPα Enhance Innate and Adaptive Immune Responses to Promote Anti-Tumor Activity
Post navigation
Previous:
Discovery of Monoclonal Antibodies Targeting Myeloid Checkpoint SIRPα to Enhance Anti-Tumor Immunity
Next:
A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Established Anticancer Antibodies in Patients with Advanced Malignancy
